Statin Selection and Dosing for PREVENT Score of 11%
For a patient with a PREVENT score of 11%, start moderate-intensity statin therapy with either atorvastatin 10-20 mg daily or rosuvastatin 5-10 mg daily, with rosuvastatin being approximately 2-3 times more potent per milligram than atorvastatin. 1
Key Differences Between Atorvastatin and Rosuvastatin
Potency Comparison
Rosuvastatin is significantly more potent than atorvastatin at equivalent doses:
- Rosuvastatin 5 mg achieves similar LDL-C reduction (39%) as atorvastatin 15 mg 2
- Rosuvastatin 10 mg (44% LDL-C reduction) requires atorvastatin 29 mg for equivalent effect 2
- Rosuvastatin 20 mg (50% LDL-C reduction) requires atorvastatin 70 mg for comparable results 2
This translates to rosuvastatin being 3-3.5 times more potent than atorvastatin at reducing LDL-C 2. Meta-analyses confirm rosuvastatin achieves greater LDL-C lowering at 1:1 and 1:2 dose ratios without increased adverse events 3.
Safety Profile
Both statins demonstrate comparable safety profiles with no significant differences in:
- Myalgia rates
- Liver enzyme elevations (ALT >3x ULN)
- Creatine kinase elevations (>10x ULN)
- Serious adverse events or withdrawals 3
Recent real-world data shows therapeutic equivalence for cardiovascular outcomes, though rosuvastatin showed modestly higher peripheral arterial disease risk in adults ≥65 years (HR 1.19) 4.
Recommended Dosing for PREVENT Score 11%
Clinical Context
A PREVENT score of 11% places this patient in the intermediate-risk category (7.5-19.9% 10-year ASCVD risk) 1. Current ACC/AHA guidelines recommend:
- Moderate-intensity statin therapy to reduce LDL-C by ≥30% 1
- Consider risk-enhancing factors that may favor more aggressive therapy 1
Specific Dosing Recommendations
Option 1: Atorvastatin
- Start atorvastatin 10-20 mg daily 5
- This achieves moderate-intensity LDL-C reduction (30-49%)
- Can be taken any time of day, with or without food 5
Option 2: Rosuvastatin
- Start rosuvastatin 5-10 mg daily
- Rosuvastatin 10 mg provides equivalent or superior LDL-C reduction compared to atorvastatin 20 mg 6, 2
- The JUPITER trial demonstrated rosuvastatin 10 mg achieved significant ASCVD risk reduction in intermediate-risk patients 6
Treatment Algorithm
Initiate moderate-intensity statin (atorvastatin 10-20 mg OR rosuvastatin 5-10 mg)
Assess for risk-enhancing factors that may warrant higher intensity:
- Family history of premature ASCVD
- LDL-C persistently ≥160 mg/dL
- Metabolic syndrome
- Chronic kidney disease
- Chronic inflammatory conditions
- High-risk ethnicity (South Asian)
- Elevated triglycerides ≥175 mg/dL 1
If risk-enhancing factors present, consider escalating to:
- Atorvastatin 40 mg OR Rosuvastatin 20 mg to achieve ≥50% LDL-C reduction 1
Recheck lipids at 4-12 weeks to assess adherence and response 1, 5
Target LDL-C reduction of ≥30% for intermediate risk; consider ≥50% if multiple risk-enhancing factors present 1
Critical Considerations
PREVENT vs. PCE Risk Scores
Important caveat: The PREVENT equations systematically assign lower risk estimates than the older pooled cohort equations. Using PREVENT with existing treatment thresholds could reduce statin eligibility by approximately 14.3 million US adults and potentially result in 107,000 additional cardiovascular events over 10 years 7. This suggests that a PREVENT score of 11% may warrant treatment intensity similar to what would be given for a higher PCE-calculated risk.
Cost Considerations
Generic rosuvastatin and atorvastatin are therapeutically equivalent with comparable clinical outcomes. Switching between them shows no difference in MACE rates or mortality, with potential cost savings favoring generics 8, 9.
Drug Interactions
Atorvastatin dose caps apply with certain medications 5:
- Maximum 20 mg with clarithromycin, itraconazole, or certain antivirals
- Maximum 40 mg with nelfinavir